Analysis of cantharidin-induced nephrotoxicity in HK-2 cells using untargeted metabolomics and an integrative network pharmacology analysis

Abstract

Cantharidin (CTD) is the major bioactive compound in Mylabris and has been shown to exhibit antitumor activity. However, its clinical application is relatively limited due to its potential toxic effects, especially nephrotoxicity. In this study, a UHPLC-QE/MS based metabolomics approach combined with network pharmacology was used to investigate the mechanism of CTD-induced nephrotoxicity in HK-2 cells. A total of 76 potential biomarkers and 28 disturbed metabolic pathways were identified in HK-2 cells exposed to CTD. And apoptotic protein expression levels of Caspase 3 and Bax/Bcl-2 ratio were increased in HK-2 cells exposed to CTD. In addition, combined with integrative network pharmacology analysis, the results demonstrated that CTD inhibits the glycerophospholipid and sphingolipid pathways, phosphatidylethanolamine, phosphatidylcholine, MAPK3, and PLD2. These may represent potential diagnostic markers and therapeutic targets, and may also lead to a strategy for reducing CTD-induced toxicity in the clinic.